Dyne Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+2.51%
vs ±16.7% implied · ×0.15
shaded = implied · ▲▼ = realized
No other changes.
No other changes.
Annual filing, covered
10-K parsed · Mar 2 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 2 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Dyne Therapeutics, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Dyne Therapeutics, Inc.'s 6 closest co-movers, none share that code.
Tall tick = annual report · Source: EDGAR
Largest filed tie
—
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
—
—
| Manager | Value | % base | |
|---|---|---|---|
| T. Rowe Price | $686.6M | 16.21% | +0.41% |
| BlackRockindex-like | $275.5M | 6.50% | +6.02% |
| Jupiter Topco | $266.6M | 6.29% | — |
| FMR | $248.9M | 5.88% | +25.79% |
| State Streetindex-like | $165.6M | 3.91% | +12.09% |
| Manager | Value | % base | |
|---|---|---|---|
| T. Rowe Price | $686.6M | 16.21% | +0.41% |
| BlackRockindex-like | $275.5M | 6.50% | +6.02% |
| Jupiter Topco | $266.6M | 6.29% | — |
| FMR | $248.9M | 5.88% | +25.79% |
| State Streetindex-like | $165.6M | 3.91% | +12.09% |
Bull1
Bear3
Expected move
Inputsspot 17.30exp Nov 20ATM strike 17ATM straddle 2.37IV 78%
Dyne Therapeutics, Inc.
18.05